SOM3355: a unique pharmacological profile combining VMAT1 inhibition, VMAT2-mediated dopamine modulation, and β1-adrenergic antagonism for the treatment of movement and neuropsychiatric disorders.

bevantolol (SOM3355) - SOM Biotech

(+)-α-dihydrotetrabenazine (ADE 513) - Adeptio Pharma

http://www.ncbi.nlm.nih.gov/pubmed/42239508

Emily S Turilli-Ghisolfi; Knut Teigen; Oscar Huertas; Rossella Medori; Silvia Panigone; Svein Isungset Støve; Trond-André Kråkenes

Jun 5, 2026